

**Progression of urothelial carcinoma *in situ* of the urinary bladder:
a switch from luminal to basal phenotype and related therapeutic implications**

Isabella Barth, Ursula Schneider, Tobias Grimm, Alexander Karl, David Horst, Nadine T. Gaisa,

Ruth Knüchel and Stefan Garczyk

Corresponding author:

Prof. Dr. med. Ruth Knüchel
Institute of Pathology
University Hospital RWTH Aachen
Pauwelsstrasse 30, 52074 Aachen, Germany
Email: rkneuchel-clarke@ukaachen.de

	all CIS cases n=156 (100%)	
pre-treatment		
previously untreated CIS	96	(62%)
previous BCG treatment	37	(24%)
previous Mitomycin treatment	10	(6%)
previous BCG and Mitomycin treatment	4	(3%)
no data available	9	(6%)
type of biopsy		
TUR	146	(94%)
Cystectomy	10	(6%)
Variant CIS growth pattern		
pagetoid CIS cell spread	37	(24%)
denuding morphology	36	(23%)
pagetoid and denuding growth pattern	10	(6%)
no pagetoid or denuding growth pattern	73	(47%)

Online resource 2: Clinicopathological data

Abbreviations: BCG – Bacillus Calmette-Guérin, CIS – Carcinoma in situ, TUR – Transurethral resection